Thermo Fisher Scientific Inc. $TMO Shares Bought by Hazlett Burt & Watson Inc.

Hazlett Burt & Watson Inc. boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.3% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 1,760 shares of the medical research company’s stock after purchasing an additional 233 shares during the period. Hazlett Burt & Watson Inc.’s holdings in Thermo Fisher Scientific were worth $714,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC grew its position in Thermo Fisher Scientific by 2.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 106,999 shares of the medical research company’s stock worth $45,097,000 after purchasing an additional 2,062 shares during the period. GW Henssler & Associates Ltd. grew its position in Thermo Fisher Scientific by 0.9% during the 2nd quarter. GW Henssler & Associates Ltd. now owns 37,057 shares of the medical research company’s stock worth $15,025,000 after purchasing an additional 347 shares during the period. Mitchell Sinkler & Starr PA grew its position in Thermo Fisher Scientific by 11.3% during the 2nd quarter. Mitchell Sinkler & Starr PA now owns 692 shares of the medical research company’s stock worth $281,000 after purchasing an additional 70 shares during the period. Criteria Caixa S.A.U. acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $6,171,000. Finally, Legal Advantage Investments Inc. grew its position in shares of Thermo Fisher Scientific by 1.2% during the 2nd quarter. Legal Advantage Investments Inc. now owns 8,329 shares of the medical research company’s stock valued at $3,377,000 after acquiring an additional 100 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TMO. Hsbc Global Res cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Evercore ISI raised their target price on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Barclays raised their target price on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $593.43.

Thermo Fisher Scientific Trading Down 1.8%

TMO stock opened at $524.95 on Monday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The stock has a market cap of $198.23 billion, a price-to-earnings ratio of 30.36, a PEG ratio of 2.85 and a beta of 0.77. The business’s 50-day moving average is $488.68 and its 200 day moving average is $447.49.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the company posted $5.37 EPS. The business’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 in the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.